Inhibition of phospholipase D2 induces autophagy in colorectal cancer cells.
- Author:
Won Chan HWANG
1
;
Mi Kyoung KIM
;
Ju Hyun SONG
;
Kang Yell CHOI
;
Do Sik MIN
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- MeSH: Autophagy/*drug effects; Cell Line, Tumor; Colorectal Neoplasms/enzymology/*genetics/*therapy; Genetic Therapy; HCT116 Cells; Humans; Phospholipase D/*antagonists & inhibitors/*genetics/metabolism; Quinolines/*pharmacology; *RNA Interference; RNA, Small Interfering/genetics/pharmacology; Signal Transduction/drug effects; Spiro Compounds/*pharmacology
- From:Experimental & Molecular Medicine 2014;46(12):e124-
- CountryRepublic of Korea
- Language:English
- Abstract: Autophagy is a conserved lysosomal self-digestion process used for the breakdown of long-lived proteins and damaged organelles, and it is associated with a number of pathological processes, including cancer. Phospholipase D (PLD) isozymes are dysregulated in various cancers. Recently, we reported that PLD1 is a new regulator of autophagy and is a potential target for cancer therapy. Here, we investigated whether PLD2 is involved in the regulation of autophagy. A PLD2-specific inhibitor and siRNA directed against PLD2 were used to treat HT29 and HCT116 colorectal cancer cells, and both inhibition and genetic knockdown of PLD2 in these cells significantly induced autophagy, as demonstrated by the visualization of light chain 3 (LC3) puncta and autophagic vacuoles as well as by determining the LC3-II protein level. Furthermore, PLD2 inhibition promoted autophagic flux via the canonical Atg5-, Atg7- and AMPK-Ulk1-mediated pathways. Taken together, these results suggest that PLD2 might have a role in autophagy and that its inhibition might provide a new therapeutic basis for targeting autophagy.
